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1. INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases 
affecting over 1/3 of the population in the Western world. The histopathology spectrum 
of NAFLD includes steatosis alone, steatosis with inflammation and steatohepatitis (non 
alcoholic steatohepatitis/NASH) that includes necroinflammation with or without 
fibrosis. (1). The pathogenesis of NAFLD/NASH is not fully understood yet. Recently 
the role of innate immunity has been implicated in the pathogenesis of NASH (1). 
Pattern recognition Toll-like receptors (TLR) and NOD-like receptors (NLR) are key 
components of the innate immune system in the recognition of pathogens, but they also 
sense danger signals released from damaged cells (94). The inflammation induced via 
the TLRs or NLRs contribute to the pathogenesis of several autoinflammatory diseases. 
Fatty liver is highly sensitive to the TLR4 ligand lipopolysaccharide (LPS or 
endotoxin), that is a bacterial wall component of Gram-negative bacteria. Furthermore, 
increased plasma endotoxin levels were detected in steatohepatitis both in mice and 
humans. However, the role of the TLR4-MD2 receptor complex in NASH is yet to be 
evaluated. 
Inflammasomes, large caspase-1-activating multiprotein complexes that sense both 
danger signals through the intracellular NLRs, are major contributors to inflammation. 
The NALP3 inflammasome is involved in sensing endogenous danger signals, and 
promotes the cleavage and maturation of the pro-inflammatory cytokine pro-IL-1
promote/sustain inflammation. The inflammasome activation is a two step process, in 
which the first step usually by a TLR ligand such as LPS induce the up-regulation of the 
inflammasome and pro-IL-  cell-
specific expression and role of the inflammasome in the liver are yet to be evaluated in 
NASH. 
While the factors determining progression of NASH are yet to be fully defined, the 
clinical importance of increased susceptibility of the fatty liver to viral infections is 
emerging. Co-morbidity of NASH with viral infections caused by RNA viruses, such as 
hepatitis C and HIV remains a clinical challenge. The pathomechanism behind the 
impaired antiviral immuntity is not fully clarified yet. 
 
 
2. AIMS 
 
The aim of thesis was to explore the role of innate immunity in the pathogenesis of 
NASH. 
 
2/1. The first part of the work focus on the role of the Gram negative bacterial wall 
component endotoxin and its receptor, Toll-like receptor 4 in the development of diet-
induced steatohepatitis and fibrosis. To perform the experiments we employed wild 
type, TLR4- and MD2 (myeloid differentiation factor 2)-deficient mice fed with 
methinone-choline deficient (MCD) diet to induce steatohepatitis. MD2 is the part of 
the LPS-sensing TLR4 receptor complex.  
 
2/2. The second part of the work was designed to investigate the role of the pro-
inflammatory cytokine IL-
the IL- -maturation in the pathogenesis of NASH. We wanted to answer the following 
questions:  
 Is there inflammasome activation and increased IL-
of liver steatosis and steatohepatitis?  
 Which cell type(s) is/are involved in the inflammasome activation in NASH? Do 
hepatocytes express the inflammasomes?  
 What does activate the inflammasome in NASH? 
 Does the inflammasome activation contribute to the development / progression of 
NASH? To perform the experiments we employed the MCD diet model of 
steatohepatitis on wild type, ASC, caspase-1 and IL-1R deficient mice.  
 Is there increased inflammasome expression in liver biopsy samples of NASH 
patients? 
 
2/3. In the third part of the work we aimed to explore the pathogenesis behind the 
susceptibility of fatty liver to viral diseases. We tested the hypothesis that mice with 
steatohepatitis are more susceptible to virus induced liver injury. To perform the 
experiment we employed mice fed with MCD diet to induce steatohepatitis and 
challenged them with Poly I:C to mimic viral infection.   
Arra ker -
-
 
  We investigated the intracellular signaling cascade step by step 
induced by Poly I:C. 
 
 
 
METHODS 
 
Animal studies 
This study was approved by Institutional Animal Use and Care Committee (IACUC) at 
University of Massachusetts (UMASS) Medical School.  
Wild type (wt) C57Bl/6 mice were fed with either methionine-choline deficient (MCD) 
diet for 5 or 8 weeks; or high fat diet (HFD) for 4 weeks or 9 months. Control mice 
received either an MCD-identical, but DL-methionine and choline bitartrate 
supplemented (MCS) diet, or regular rodent chow diet. We also used 9 weeks old, 
female leptin deficient (ob/ob; B6.V-Lep ob/J) mice with their own age and gender-
matched control group. TLR4 ligand lipopolysaccharide (LPS) or TLR3/RLR ligand 
polyinosinic:polycytidylic acid (Poly I:C), a synthetic double stranded RNA; or TLR9 
ligand CpG-ODN were injected intaperitoneally for 2 or 6 hours. The following knock-
out mice were used: TLR4-, MD-2, ASC-, caspase-1or IL-1R-defcient mice with their 
appropriate controls.  
We performed biochemical analysis and cytokine measurements (serum alanine 
aminotransferase, serum cytokines [ -6, IL-  liver 
triglyceride and thiobarbituric reactive substances [TBARS]; histopathological analysis 
(hematoxylin-eosin, picro-sirius red, OilRed O staining, F4/80 and smooths muscle 
actin immunohistochemistry). RNA and protein (whole cell, mitochondrial and 
cytoplasmic) were isolated from liver tissue and used for real time PCR and Western 
blot (SDS-PAGE and native gel electrophoresis, immunoprecipitation) analysis, 
respectively.  The following functional assays were performed: caspase-1, -3, NADPH 
activity and cell cytotoxicity assays. 
In vitro experiments 
Hepatocytes and liver mononuclear cells were isolated from mice, and we also 
employed mouse hepatoma (Hepa1-6) and monocyte-macrophage (RAW 264.7) cell 
lines.The cells were stimulated with LPS, saturated and non-saturated fatty acids 
(palmitic, oleic, linoleic acid) or their combinations with or without pan-caspase 
inhibitor. Poly I:C was used to stimulate hepatocytes with or without Lipofectamin 
2000. Liver mononuclear cells were analysed by flow cytometry for and ED1 
(CD68) positivity.  
 
Human liver samples 
The study meets the ethical guidelines of the 1975 Declaration of Helsinki and was 
approved by the Committee for the Protection of Human Subjects in Research at the 
University of Massachusetts.  All participants gave a written consented to participate in 
the study. Human liver tissue was obtained from biopsies from six, clinically and 
biopsy-proven NASH patients. Human liver tissue from chronic hepatitis C infected 
patients (n=5) were used as diseased controls. Human normal liver (n=4) total RNA was 
purchased from OriGene Technologies.  
 
 
 
RESULTS 
 
Deficiency in myeloid differentiation factor-2 (MD2) and toll-like receptor 4 
(TLR4) expression attenuates non-alcoholic steatohepatitis and fibrosis in mice 
 
MD-2 or TLR4 protects from MCD diet-induced liver fat deposition and inflammation 
MD-2 and TLR4 complex is the major receptor for endotoxin that has been shown to 
contribute to activation of the inflammatory cascade in alcoholic steatohepatitis (ASH) 
leading to liver damage. Given the common pathophysiological features of ASH and 
NASH, we aimed to identify the role of MD-2/ TLR4 complex in an experimental 
model of NASH.  
 Mice of control genotypes fed a methionine-choline-deficient (MCD) diet for 8 weeks 
developed significant hepatic steatosis and inflammation. MD-2- and TLR4-deficient 
mice on MCD diet showed lower liver fat accumulation and inflammatory cell 
infiltration compared to the mice of control genotypes. Latter one was showed by the 
reduced number of F4/80+ and CD68+ TNF -producing macrophages, as well as by the 
lower serum  levels in the knock out mice compared to the mice of control 
genotypes. A significant increase in serum alanine aminotransferase (ALT), suggesting 
on-going liver damage, was observed in the MCD-diet-fed control genotype mice, 
however, the ALT increase was significantly attenuated in MD-2- and TLR4-deficient 
mice. 
 
MD-2 and TLR4 deficiency attenuates oxidative stress  
Increased lipid peroxidation and oxidative stress are keys in development of non 
alcoholic steatohepatitis. We identified significantly higher levels of liver thiobarbituric 
acid substances (TBARS), indicative of lipid peroxidation, in MCD-diet compared to 
the MCS diet-fed genotype control mice.  Consistent with our hypothesis that 
MD2/TLR4 complex plays a role in NASH, we found significantly reduced induction of 
TBARS in the livers of MCD-diet-fed MD-2- and TLR4-deficient mice. NADPH 
oxidases play an important role in the generation of reactive oxygen radicals.  
NADPH oxidase expression revealed a significant upregulation and activation of the 
NADPH oxidase complex (p47phox, p67phox, gp91phox, p22phox) in MCD-diet-fed 
animals of control genotypes. Deficiency in MD-2 or TLR4 abrogated the MCD-
induced up-regulation of all of the NADPH oxidase subunits, suggesting that NADPH-
mediated oxidative stress is dependent on MD-2 and TLR4 expression in this model.  
 
MD-2 and TLR4 deficiency protects from NASH-associated liver fibrosis  
A key clinical challenge in human NASH is its progression to fibrosis and 
cirrhosis. MCD diet feeding for 8 weeks results in hepatic stellate cell (HSC) activation 
and fibrosis in mice
staining and the increased expression of the fibrosis-  
). We found that the deficiency of either MD-2 or TLR4 attenuated significantly 
the MCD-diet induced fibrosis compared to the mice of control genotypes. Liver 
fibrosis involves inflammation-driven tissue remodeling; matrix metalloproteinases 
(MMP) and their specific tissue inhibitors (TIMPs) closely regulate the metabolism of 
the extracellular matrix. Bothe the MMP-2 and TIMP-1 expression were increased in 
MCD diet-fed mice compared to MCS-diet-fed mice of control genotypes; the induction 
of these genes was significantly attenuated in the absence of MD-2 or TLR4 expression.  
 
 
 
Fatty acids and endotoxin activates the inflammasome in non-alcoholic  
steatohepatitis 
 
Given the role of endotoxin and TLR4, and the fact that there is crosstalk between TLR 
and NLR signaling, furthermore, that endotoxin is a known activator of inflammasomes, 
next step we aimed to investigate the role of inflammasomes in the pathogenesis of 
NASH. Inflammasomes are large, intracellular multiprotein complexes that sense 
intracellular danger signals via NOD-like receptors and lead to caspase-1 activation and 
IL-  secretion. 
 
MCD diet-induced steatohepatitis is associated with increased IL-
inflammasome activation in the liver  
The MCD diet model of non-alcoholic steatohepatitis (NASH) is characterized by 
steatosis and prominent inflammation. Here we found that among other pro-
inflammatory cytokines the levels of serum IL- -  mRNA and 
protein were significantly increased in the livers of MCD diet-fed mice compared to 
MCS controls. Consistent with this we found increased expression and activation of the 
NALP3 inflammasome complex (NALP3, ASC, pro-caspase-1) in the livers of MCD 
diet-fed mice compared to MCS-controls. NALP3 forms complex with pro-caspase-1 
via the adaptor ASC and after the auto-activation of the caspase-1 enzyme, the active 
caspase-1 cleaves and activates pro-IL- .  The increased caspase-1 activity was 
accompanied by higher cleaved, mature IL-  protein levels in MCD-steatohepatitis 
compared to the controls. 
Long-term, but not short-term high fat diet feeding is associated with  inflammasome 
activation in the liver  
While the MCD diet model induces NASH, high fat diet results in steatosis after 4 
weeks and evidence of inflammation occurs after prolonged HFD feeding. Consistent 
-expression only in livers with 9-month 
and not with 4-week HFD feeding. We found that 4-week HFD resulted in no increase 
in inflammasome expression, while 9-month HFD induced significant up-regulation of 
the NALP3 inflammasome complex at the mRNA level. Inflammasome activation was 
indicated by increased caspase-1 activity and higher liver mature IL-
9-month but not in 4-week HFD groups compared to their corresponding controls.  
Liver steatosis without features of inflammation is also prominent in leptin deficient 
(ob/ob) mice. We found no inflammasome activation in ob/ob mice compared to their 
controls.  
 
Increased inflammasome expression in human NASH  
There was a significant increase in inflammasome gene expression including NALP3, 
pro-caspase-1, ASC and pannexin-1 in livers from NASH patients compared to healthy 
controls.  Liver samples from chronic HCV infected patients also showed increased 
inflammasome expression, however, to a lower extent than NASH livers. 
 
LPS induces upregulation of the inflammasome in the liver  
In vivo stimulation with LPS, lead to up-regulation of the hepatic inflammasome 
components at the mRNA level and increased IL-1 in both MCD 
and MCS diet-fed mice. However, the LPS-induced inflammasome expression was 
higher in MCD diet-fed mice compared to MCS controls.  
 
Inflammasome is upregulated in hepatocytes in NASH  
Next step, we sought to evaluate whether inflammasome activation occurs in 
hepatocytes. To date inflammasome expression and activation has been mostly studied 
in innate immune cells. We found that primary hepatocytes of MCD diet-fed mice 
showed increased expression of NALP3, ASC, pro-caspase-1, pannexin-1 and pro-IL-
1beta mRNA compared to controls, but not the liver mononuclear cells.   
Fatty acids and LPS induce inflammasome activation in hepatocytes  
Both circulating fatty acids and gut-derived endotoxins (LPS) contribute to the 
pathogenesis of NASH. We found increased serum endotoxin levels in mice with 
steatohepatitis. Palmitic acid, a saturated fatty acid induced increased expression of 
NALP3 mRNA in isolated mouse hepatocytes, as well as Hepa 1-6 cells and RAW 
macrophages.  LPS also induced NALP3 mRNA expression in the hepatocytes. 
However, LPS alone did not result in inflammasome activation and IL- secretion, and 
palmitic acid also induced only moderate increase in IL- without 
detectable caspase-1 activation. Significantly higher levels and earlier IL-
was seen in hepatocytes with palmitic acid pre-treatment followed by LPS stimulation 
compared to PA or LPS treatment alone, suggesting sensitization in hepatocytes. 
The observation that palmitic acid alone induced IL-
evidence of caspase-1 activation prompted us to evaluate alternative mechanisms for IL-
1 cleavage in hepatocytes. While pro-IL-
inflammasome-mediated caspase-1 activation, it can also be cleaved by caspase-8.  
Indeed, we found that palmitic acid, but not LPS, resulted in caspase-8 activation and 
more importantly, caspase-8 activation was not increased by the combination of 
palmitic acid and LPS. These results suggested that caspase-8 could be involved in the 
IL- -treated hepatocytes.  
 
Palmitic acid-treated hepatocytes transmit danger signals and induce inflammasome 
activation in liver mononuclear cells  
Caspase-8 is also induced in apoptosis. Increased LDH release in hepatocytes after PA 
treatment indicated induction of cell death. We determined that up-regulation of NALP3 
and IL- palmitic acid was caspase-dependent because these events were 
prevented by addition of the pan-caspase inhibitor, ZVAD in hepatocytes. This 
observation also suggested that damage-associated molecules generated in apoptotic 
hepatocytes rather than palmitic acid itself could contribute to inflammasome activation. 
Furthermore, these danger molecules can activate the inflammasome in the liver 
mononuclear cells. PA-free supernatants from PA-pretreated hepatocytes induced 
upregulation of NALP3 and IL- RNA in the LMNCs in a ZVAD-dependent 
manner.   
Deficiency of the inflammasome components does not prevent liver injury and fat 
deposition in the MCD-diet model of NASH  
Next step we tested the physiological significance of inflammasome activation in 
NASH using various knock-out mice. Neither the deficiency of ASC (inflammasome 
adaptor), nor the deficiency of caspase-1 (inflammasome effector) prevented the MCD 
diet-induced liver injury, indicated by the high ALT levels both in the wild type and 
knock out genotypes. ASC-deficiency did not influence the development of steatosis 
and we detected compareable IL-  levels in the liver of bothe the knock out and the 
control genotypes. This suggested that inflammasomes that do not need ASC as an 
adaptor molecule (eg. NALP1) might also contribute to the pathogenesis of NASH.   
However, the deficiency of caspase-1 did not influence either the active IL-  levels in 
the liver suggesting the possibility of alternative IL-  cleavage. As we mentioned 
above, among others, caspase-8 is also able to cleave IL- . Consistent with this we 
found increased caspase-8 activity in MCD diet-induced steatohepatitis in wild type, 
ASC- and caspase-1-deficient mice. This suggested that caspase-8 might compensate 
the caspase-1 deficiency in terms of IL-  
 
Interleukin-1 receptor deficiency attenuates hepatic steatosis, but does not prevent 
MCD-diet-induced liver injury or fibrosis  
To further explore the role of IL-1 in NASH, we employed IL-1 receptor (IL-1R) 
knock out mice. We found attenuated steatosis in MCD-diet fed IL-1R KO mice 
compared to WT controls. In contrast, IL-1R deficiency failed to prevent liver injury 
and fibrosis in MCD-diet-fed mice Latter one was shown by the collagene mRNA 
 
 
 
 
Mitochondrial antiviral signaling protein defect links impaired antiviral response 
and liver injury in steatohepatitis in mice  
 
Type-I IFN induction is decreased in steatohepatitis in response to poly I:C stimulation 
Polyinosinic-polycytidylic acid (poly I:C), a synthetic double-stranded RNA (dsRNA), 
is a surrogate for viral infection. Double stranded RNA is recognized by TLR3 and 
helicase receptors and induces robust Type-I IFN response leading to anti-viral 
immunity. We found significantly decreased poly I:C-induced Type-I interferon 
production in mice with MCD-steatohepatitis compared to MCS controls. There were 
significantly lower serum , liver and and mRNA levels, as well 
as hepatic mRNA levels of Type-I IFN inducible genes (ISG56, ISG15) in MCD-
steatohepatitis compared to MCS controls after poly I:C stimulation.   
 
Impaired Type-I IFN induction in steatohepatitis is restricted to the RIG-I/Mda5 
pathway  
To further evaluate the significance of impaired Type-I IFN induction in steatohepatitis, 
we employed stimulations that induce Type-I IFNs via receptor pathways different from 
dsRNA recognition by TLR3 and its adapter, TRIF, or RIG-I/Mda5 and their adapter 
MAVS, respectively. LPS is recognized by TLR4 and uses the adapters TRIF and 
MyD88, while CpG DNA, a ligand for TLR9 solely utilizes the MyD88 adapter in 
Type-I IFN induction. The fact that impaired Type-I IFN production in steatohepatitis 
was observed only in case of dsRNA stimulation suggested a selective impairement of 
the helicase receptor signaling and not of the TLR3/TRIF-dependent pathways.   
 
Abnormal MAVS function in NASH involves decreased protein levels, dissociation 
from the mitochondria and impaired oligomerization  
The adapter molecule MAVS is critical for the downstream signaling of helicase 
receptors and its dysfunction impairs proinflammatory cytokine and interferon induction 
.  Consistent with decreased 
induction of Type-I IFN, we found decreased levels of MAVS protein in whole liver 
lysates of MCD-diet fed mice compared to controls. In search of possible mechanisms 
for decreased MAVS protein levels despite of the increased MAVS mRNA expression, 
we found higher mRNA expression of the PSMA7 subunit of proteasome in MCD 
steatohepatitis. PSMA7 can negatively regulate MAVS-mediated immune responses 
and promotes proteosomal degradation. Immunoprecipitation experiments revealed 
increased association between MAVS and PSMA7 in fatty livers compared to controls. 
We also found that steatohepatitis resulted in decreased mitochondria-associated MAVS 
protein levels and decreased MAVS oligomerization compared to controls. Both the 
mitochondrial localization and oligoemrization of MAVS is crucial for Mda5/RIG-I 
activation. Consistent with this, we found impaired poly I:C-induced IRF3 
phosphorilation in MCD-steatohepatitis compared to the controls.  
 
Mitochondrial damage occurs in the fatty liver  
Mitochondrial dysfunction plays a role in the pathogenesis of NASH and upon 
mitochondrial damage, its content leaks into the cytosol triggering diverse signaling 
pathways, including apoptosis. Indeed, mitochondrial damage was indicated by 
relocation of cytochrome C from the mitochondria to the in MCD-steatohepatitis 
compared to the controls. Mitochondrial damage in NASH has been linked to excessive 
levels of reactive oxygen species (ROS). We detected significantly increased liver 
TBARS levels indicating ROS-induced lipid peroxidation at baseline and after poly I:C 
stimulation in steatohepatitis. Mitochondrial damage might contribute to the abnormal 
MAVS localization and function. In addition, we found increased caspase-8 and -1 
activity in MCD-steatohepatitis.  Both enzymes has been shown to cleave and inactivate 
MAVS protein.  
 
Increased poly I:C-induced liver damage occurs without excessive pro-inflammatory 
cytokine induction in steatohepatitis  
Poly I:C challenge significantly increased liver injury in MCD diet-fed mice indicated 
by significantly increased serum ALT levels compared to MCS controls mice. Because 
dsRNA-induced activation of helicase receptors leads to Type-I IFN induction as well 
-inflammatory cytokines, we sought to 
evaluate whether the increased liver damage was the consequence of enhanced pro-
inflammatory cytokine production in steatohepatitis.  At baseline, MCD diet-fed mice 
-6 and IL-
-6 and IL-
both in controls and MCD-diet fed groups, the extent of pro-inflammatory cytokine 
protein and mRNA induction was significantly lower in MCD compared to MCS diet-
fed mice. These data suggested that it is less likely that the pro-inflammatory cytokines 
account for the increased liver damage in NASH. Since, previous studies showed a 
crucial role for NK cells in poly I:C induced liver injury, we next investigated the 
possible role of NK cells.  We found increased mRNA expression of the NK-activating 
ligands (Pan-Rae, Rae- , Mult-1) in MCD-steatohepatitis, but poly I:C did not induce 
a further increase in the expression of these ligands. 
 
Poly I:C promotes a switch from apoptosis to necrosis and increases RIP3 expression in 
steatohepatitis  
Hepatocyte apoptosis is a key component of liver damage in NASH. Consistent with 
this we found higher caspase-3 activity in MCD diet-fed mice compared to the controls.  
Poly I:C induced apoptosis in the livers of MCS diet-fed control mice indicated by the 
higher caspase-3 activity, but it did not increase further the apoptosis in MCD-
steatohepatitis. In contrast, the poly I:C-induced serum HMGB1 levels were 
significantly higher in the MCD diet-fed mice comapred to MCS controls suggesting 
that the presence of necrosis. A recently identified master regulator between apoptosis 
and necrosis is the protein kinase receptor-interacting protein 3 (RIP3). We found 
increased levels of RIP3 mRNA and protein in livers of MCD- compared to MCS-diet-
fed controls. In control mice poly I:C stimulation induced upregulation of RIP3 protein 
expression at 2 hours post-stimulation which returned to baseline by 6 hours; in 
contrast, there was sustained induction of RIP3 in steatohepatitis after poly I:C 
challenge. We further identified a positive correlation between RIP3 and liver HMGB1 
expression. Collectively, these data suggested that pathways that promote necrosis are 
preferentially upregulated in steatohepatitis after a viral challenge, at least in part due to 
the regulatory involvement of RIP3. 
 
Altered MAVS and RIP3 mRNA expression in human NASH  
Consistent with our observations in the animal models, we found higher MAVS, 
PSMA7 and RIP3 mRNA levels in human NASH livers comapred to healthy controls 
and compared the hepatitis C infected patients.  
 
 
 
CONCLUSIONS, SUMMARY 
 
In the present study we demonstrate several novel findings that support the substantial 
role of innate immunity in the pathogenesis of NASH.  
 
The following conclusions can be drawn based on our results:  
 
1. Deficient integrity of the danger receptor complex, including TLR4 or its co-receptor 
MD-2, is protective from MCD-diet-induced liver steatosis, inflammation, correlates 
with attenuated liver injury and confers protection from development of liver fibrosis in 
MCD-diet-induced NASH.  
2. There is up-regulation and activation of the NALP3 inflammasome complex and 
therefore increased IL-  in NASH in mouse models as well as in human 
livers. Our data also suggest that inflammasome activation occurs in steatohepatitis and 
not in early steatosis in mice.  
3. While increased circulating endotoxin likely contributes to inflammasome activation, 
exogenous LPS can amplify inflammasome activation and IL-
steatohepatitis.  
4. Inflammasome activation and IL- on occur in isolated hepatocytes in NASH.  
5. Saturated, but not un-saturated, fatty acids increase inflammasome expression and 
sensitize hepatocytes to IL-  
6. Fatty acids not only upregulate inflammasome but also induce apoptosis and release 
of danger signals in hepatocytes.  
7. These danger signals induce inflammasome activation in liver mononuclear cells 
demonstrating a cross-talk between injured hepatocytes and inflammatory cells in 
NASH.  
8. The IL-1 signaling contributes to the development of liver steatosis; however, neither 
the lack of the inflammasome effector caspase-1, nor IL-1R deficiency prevents liver 
injury and/or fibrosis in MCD diet-induced steatohepatitis. 
9. There is increased inflammasome expression in the liver of NASH patients. 
 
Finally, here we report novel findings related to the impaired capacity of the fatty liver 
to respond to dsRNA and related viral challenges:  
10. Livers with steatohepatitis fail to activate anti-viral innate immune pathways to 
produce Type I IFNs in response to a double-stranded RNA challenge.  
11. The MAVS adapter, which is required for Type-I IFN induction after recognition of 
dsRNA by the helicase receptors RIG-I and Mda5, is dissociated from the mitochondria 
to the cytosol and shows impaired oligomerization and function in steatohepatitis.  
12. The displacement of MAVS from mitochondria is associated with oxidative stress 
and instead of upregulation of the apoptosis cascade, poly I:C promotes necrosis via 
increased expression of RIP3 in steatohepatitis.  
13. Fourth, we show that dsRNA challenge results in increased liver damage in spite of 
-inflammatory cytokine induction in a diet-induced model of 
NASH. 
 
Our novel data might contribute to better understand the pathogenesis of non alcoholic 
steatohepatitis and therefore to develop targeted therapy.  
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